ARDX
NEUTRAL
$5.78
Live
Ardelyx, Inc. · NASDAQ
Target $16.1
(+178.5%)
$3.21
52W Range
$8.4
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$1.42B
P/E
N/A
ROE
-36.2%
Profit margin
-15.1%
Debt/Equity
1.4
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
72%
Ardelyx (ARDX) exhibits a Piotroski F-Score of 4/9, indicating weak financial health and limited operational stability, with no Altman Z-Score available to assess bankruptcy risk. The company trades at a forward P/E of 11.08 and a price/sales ratio of 3.48, suggesting modest valuation relative to peers, though profitability remains negative with a -15.12% profit margin and negative ROE. Despite a 7.8% YoY revenue growth and improving earnings surprise trends, insider selling activity over the past six months—totaling $1.35M in sales—raises governance concerns. Analysts maintain a strong_buy consensus with a $16.10 target, implying significant upside, but this is tempered by high volatility and lack of dividend yield.
Key Strengths
Forward P/E of 11.08 is relatively attractive for a biotech with growth potential
Positive revenue growth at 7.8% YoY and improving earnings surprise trends
Strong gross margin of 72.73% indicates efficient product monetization
Analyst consensus remains strong_buy with a $16.10 target price
High gross margins and improving Q/Q EPS growth (52.9%) suggest operational improvement
Key Risks
Piotroski F-Score of 4/9 signals weak financial health and operational instability
Negative ROE (-36.21%) and ROA (-5.46%) indicate poor capital efficiency
Debt/Equity ratio of 1.40 is elevated for a biotech, raising leverage concerns
Insider selling activity totaling $1.35M in six months suggests bearish sentiment among executives
No dividend, no free cash flow, and negative earnings history limit traditional valuation metrics
AI Fair Value Estimate
Based on comprehensive analysis
$12.5
+116.3% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
45
Moderate
58
72
55
42
0
AI Verdict
neutral
Key drivers: Mixed financial health (Piotroski 4/9), Positive revenue and earnings momentum, High insider selling pressure, Attractive forward P/E relative to sector, Lack of profitability and cash flow
Confidence
75%
Value
58/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 11.08 is below sector average (164.66)
- Price/Sales of 3.48 is reasonable for a biotech with growth
- No Graham Number available, but forward P/E suggests undervaluation relative to peers
Watchpoints
- Negative earnings and ROE undermine traditional valuation
- No intrinsic value estimate due to lack of stable earnings
- Stock trades at a premium to historical lows despite negative fundamentals
Future
72/100
Ref Growth rates
Positives
- 7.8% YoY revenue growth and improving earnings surprise trends
- Q/Q EPS growth of +52.9% indicates accelerating performance
- Recent quarters show positive surprises (e.g., +41.5%, +127.7%)
- Analyst target implies 178% upside from current price
- High growth expectations embedded in market pricing
Watchpoints
- No forward earnings guidance or PEG ratio available
- Profitability remains negative despite growth
- Sustained growth may be dependent on single-product pipeline
Past
55/100
Ref Historical trends
Positives
- 2 out of last 4 quarters beat estimates
- Average earnings surprise of +13.85% over last 4 quarters
- Historical EPS growth of +27.3% YoY and +52.9% Q/Q
- Several quarters with large positive surprises (e.g., +2802.7%, +2486.2%)
Watchpoints
- Frequent negative surprises in prior quarters (e.g., -126.7%, -100.0%)
- Inconsistent earnings delivery across multiple quarters
- Negative earnings in 20 of 25 quarters tracked
- High volatility in actual vs. estimated results
Health
42/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 4.32 and quick ratio of 3.80 indicate strong liquidity
- No Altman Z-Score available, but high liquidity may mitigate distress risk
Watchpoints
- Piotroski F-Score of 4/9 is below threshold for financial stability
- Negative ROE and ROA indicate poor capital utilization
- Debt/Equity of 1.40 is high for a biotech with negative earnings
- No free cash flow or operating cash flow data available
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength score of 0/100
- No history of dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$5.78
Analyst Target
$16.1
Upside/Downside
+178.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ARDX and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ARDX
Ardelyx, Inc.
Primary
|
-17.1% | +46.3% | +6.6% | -12.6% | -20.4% | -6.6% |
|
PRCT
PROCEPT BioRobotics Corporation
Peer
|
-40.1% | -32.1% | -52.6% | -23.8% | -3.9% | +8.4% |
|
NVAX
Novavax, Inc.
Peer
|
-96.2% | -8.1% | +36.0% | -2.5% | -13.8% | +3.2% |
|
BCRX
BioCryst Pharmaceuticals, Inc.
Peer
|
-25.9% | -38.3% | -12.2% | -20.6% | -11.8% | +1.9% |
|
IMTX
Immatics N.V.
Peer
|
-10.0% | +69.3% | +162.7% | +0.7% | +4.0% | +0.8% |
ARD
Ardelyx, Inc.
Primary
5Y
-17.1%
3Y
+46.3%
1Y
+6.6%
6M
-12.6%
1M
-20.4%
1W
-6.6%
PRC
PROCEPT BioRobotics Corporation
Peer
5Y
-40.1%
3Y
-32.1%
1Y
-52.6%
6M
-23.8%
1M
-3.9%
1W
+8.4%
NVA
Novavax, Inc.
Peer
5Y
-96.2%
3Y
-8.1%
1Y
+36.0%
6M
-2.5%
1M
-13.8%
1W
+3.2%
BCR
BioCryst Pharmaceuticals, Inc.
Peer
5Y
-25.9%
3Y
-38.3%
1Y
-12.2%
6M
-20.6%
1M
-11.8%
1W
+1.9%
IMT
Immatics N.V.
Peer
5Y
-10.0%
3Y
+69.3%
1Y
+162.7%
6M
+0.7%
1M
+4.0%
1W
+0.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
11.08
PEG Ratio
N/A
P/B Ratio
8.46
P/S Ratio
3.48
EV/Revenue
3.4
EV/EBITDA
-36.57
Market Cap
$1.42B
Profitability
Profit margins and return metrics
Profit Margin
-15.12%
Operating Margin
4.07%
Gross Margin
72.73%
ROE
-36.21%
ROA
-5.46%
Growth
Revenue and earnings growth rates
Revenue Growth
+7.8%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.4
Moderate
Current Ratio
4.32
Strong
Quick Ratio
3.8
Excellent
Cash/Share
$1.08
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-19
$N/A
-100.0% surprise
2025-10-30
$N/A
+100.0% surprise
2025-08-04
$-0.08
+41.5% surprise
Healthcare Sector Comparison
Comparing ARDX against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-36.21%
This Stock
vs
-88.14%
Sector Avg
-58.9%
(Below Avg)
Profit Margin
-15.12%
This Stock
vs
-16.28%
Sector Avg
-7.1%
(Weaker)
Debt to Equity
1.4
This Stock
vs
2.66
Sector Avg
-47.4%
(Less Debt)
Revenue Growth
7.8%
This Stock
vs
124.04%
Sector Avg
-93.7%
(Slower)
Current Ratio
4.32
This Stock
vs
4.47
Sector Avg
-3.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ARDX
Ardelyx, Inc.
|
NEUTRAL | $1.42B | - | -36.2% | -15.1% | $5.78 | |
|
PRCT
PROCEPT BioRobotics Corporation
|
BEARISH | $1.42B | - | -24.9% | -31.0% | $25.14 | Compare |
|
NVAX
Novavax, Inc.
|
NEUTRAL | $1.42B | 3.25 | -% | 39.2% | $8.69 | Compare |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
NEUTRAL | $1.43B | - | -% | -1.5% | $6.79 | Compare |
|
IMTX
Immatics N.V.
|
BEARISH | $1.4B | - | -37.1% | -% | $10.43 | Compare |
ARDX
Ardelyx, Inc.
NEUTRAL
Mkt Cap
$1.4B
P/E
-
ROE
-36.2%
Price
$5.78
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-24 | RAAB MICHAEL G | Chief Executive Officer | Option Exercise | 20,833 | $20,625 |
| 2026-02-24 | RAAB MICHAEL G | Chief Executive Officer | Sale | 41,666 | $260,621 |
| 2026-02-20 | MOTT DAVID M | Director | Purchase | 333,333 | $1,946,331 |
| 2026-02-20 | RAAB MICHAEL G | Chief Executive Officer | Sale | 45,982 | $268,841 |
| 2026-02-20 | BISHOP JOHN E | Chief Operating Officer | Sale | 3,179 | $18,586 |
| 2026-02-20 | WILLIAMS LAURA A | Officer | Sale | 8,176 | $47,803 |
| 2026-02-20 | KELLIHER MICHAEL | Officer | Sale | 9,595 | $56,099 |
| 2026-02-20 | FOSTER ERIC DUANE | Officer | Sale | 10,439 | $61,034 |
| 2026-02-20 | BRADY JAMES PARKER | Officer | Sale | 2,543 | $14,868 |
| 2026-02-20 | HOHENLEITNER SUSAN | Chief Financial Officer | Sale | 2,033 | $11,886 |
| 2026-01-23 | BISHOP JOHN E | Chief Technology Officer | Stock Award | 124,330 | - |
| 2026-01-23 | RAAB MICHAEL G | Chief Executive Officer | Stock Award | 446,220 | - |
| 2026-01-23 | WILLIAMS LAURA A | Officer | Stock Award | 82,695 | - |
| 2026-01-23 | KELLIHER MICHAEL | Officer | Stock Award | 103,080 | - |
| 2026-01-23 | FOSTER ERIC DUANE | Officer | Stock Award | 137,945 | - |
RAAB MICHAEL G
Chief Executive Officer
2026-02-24
20,833 shares
·
$20,625
RAAB MICHAEL G
Chief Executive Officer
2026-02-24
41,666 shares
·
$260,621
MOTT DAVID M
Director
2026-02-20
333,333 shares
·
$1,946,331
RAAB MICHAEL G
Chief Executive Officer
2026-02-20
45,982 shares
·
$268,841
BISHOP JOHN E
Chief Operating Officer
2026-02-20
3,179 shares
·
$18,586
WILLIAMS LAURA A
Officer
2026-02-20
8,176 shares
·
$47,803
KELLIHER MICHAEL
Officer
2026-02-20
9,595 shares
·
$56,099
FOSTER ERIC DUANE
Officer
2026-02-20
10,439 shares
·
$61,034
BRADY JAMES PARKER
Officer
2026-02-20
2,543 shares
·
$14,868
HOHENLEITNER SUSAN
Chief Financial Officer
2026-02-20
2,033 shares
·
$11,886
BISHOP JOHN E
Chief Technology Officer
2026-01-23
124,330 shares
RAAB MICHAEL G
Chief Executive Officer
2026-01-23
446,220 shares
WILLIAMS LAURA A
Officer
2026-01-23
82,695 shares
KELLIHER MICHAEL
Officer
2026-01-23
103,080 shares
FOSTER ERIC DUANE
Officer
2026-01-23
137,945 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
10 analysts
Wedbush
2026-02-23
Outperform
Outperform
HC Wainwright & Co.
2026-02-20
Buy
Buy
BTIG
2026-02-20
Buy
Buy
BTIG
2026-01-29
Buy
Buy
Wedbush
2026-01-21
Outperform
Outperform
Citigroup
2026-01-09
Buy
Buy
Piper Sandler
2026-01-09
Neutral
Overweight
BTIG
2026-01-09
Buy
Buy
Piper Sandler
2025-11-04
Neutral
Neutral
Citigroup
2025-11-03
Buy
Buy
Past News Coverage
Recent headlines mentioning ARDX from our newsroom.
Newest → oldest
No matching news yet.